Abstracts tagged "dermatomyositis"

Abstract Number: 0955 • ACR Convergence 2020
Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)
Rohit Aggarwal¹, Christina Charles-Schoeman², Joachim Schessl³, Zsuzsanna Bata-Csorgo⁴, Mazen Dimachkie⁵, Zoltan Griger⁶, Sergey Moiseev⁷, Chester Oddis⁸, Elena Schiopu⁹, Jiří Vencovský¹⁰, Beckmann Irene¹¹, Clodi Elisabeth¹¹, Todd Levine¹² and and the ProDERM Investigators¹³, ¹University of Pittsburgh, Pittsburgh, PA, ²University of California, Los Angeles, Los Angeles, CA, ³Städtisches Klinikum Karlsruhe, Karlsruhe, Germany, ⁴University of Szeged, Faculty of Medicine, Szeged, Hungary, ⁵Univeristy of Kansas, Medical Center, Kansas City, KS, ⁶University of Debrecen, Debrecen, Hungary, ⁷First Moscow State Medical University, Moscow, Russia, ⁸Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁹Michigan Medicine, Ann Arbor, MI, ¹⁰Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹¹Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria, ¹²Phoenix Neurological Associates, LTD, Phoenix, AZ, ¹³Different Institutions in several countries, Vienna, Austria
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rash and progressive proximal muscle weakness. Intravenous immunoglobulin (IVIg) has long been…
Abstract Number: 1138 • ACR Convergence 2020
Estimation of Clinically Important Differences in Patient-Reported Outcomes Measurement Information System (PROMIS) Measures in Juvenile Myositis
Madison Wolfe¹, Amanda Robinson², Jin-Shei Lai³, Theresa Coles⁴, Elizabeth Gray³, Rowland Chang³, David Cella³ and Kaveh Ardalan⁵, ¹Creighton University School of Medicine, Omaha, NE, ²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Duke University, Durham, ⁵Duke University Medical Center, Durham, NC
Background/Purpose: Juvenile myositis (JM) causes weakness, rashes, pain, and fatigue, thereby impacting health-related quality of life (HRQoL). Patient-Reported Outcomes Measurement Information System (PROMIS®) measures have…
Abstract Number: 0956 • ACR Convergence 2020
An IL-18-Containing Five-Gene Signature Distinguishes Histologically Identical Dermatomyositis and Lupus Erythematosus Skin Lesions
Alex Tsoi¹, Mehrnaz Gharaee-Kermani², Celine Berthier¹, Tori Nault³, Grace Hile², Shannon Estadt⁴, Matthew Patrick¹, Rachael Wasikowski¹, Allison Billi¹, Lori Lowe¹, Tamra Reed¹, Johann Gudjonsson⁵ and J. Michelle Kahlenberg⁶, ¹University of Michigan, Ann Arbor, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Canton, MI, ⁴University of Michigan, Ypsilanti, MI, ⁵University of Michigan, Ann ArborUniversity of Michigan, ⁶Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin lesions in dermatomyositis (DM) patients are common, frequently refractory, and have prognostic significance. Histologically, DM lesions appear similar to cutaneous lupus erythematosus (CLE)…
Abstract Number: 1404 • ACR Convergence 2020
Investigating the Dermatomyositis Skin Inflammatory Infiltrate Using Image Mass Cytometry
Jay Patel¹, Spandana Maddukuri², Yubin Li³, Christina Bax⁴ and Victoria Werth³, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁴University of Pennsylvania, Department of Dermatology, Philadelphia
Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease affecting the skin and muscles, among other organs. The inflammatory infiltrate in skin has not been fully…
Abstract Number: 0995 • ACR Convergence 2020
Jo-1-Binding B Cells Undergo Limited Class-Switching but Are Biased Towards Autoreactive-Prone and Memory B Cell Subsets in Anti-histidyl-tRNA Synthetase Syndrome
Jennifer Young-Glazer¹, Alberto Cisneros², Erin Wilfong¹, Scott Smith¹, Leslie J. Crofford¹ and Rachel Bonami¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbit University Medical Center, Nashville, TN
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases traditionally classified as dermatomyositis or polymyositis, but these disorders are increasingly defined by the presence of…
Abstract Number: 1555 • ACR Convergence 2020
18F-NaF PET/CT Identifies Active Calcium Uptake in Calcinosis Due to Dermatomyositis and Scleroderma
Carrie Richardson¹, Mehrbod Javadi², Ami Shah³, Lilja Solnes², Fredrick Wigley⁴, Laura Hummers⁵ and Lisa Christopher-Stine⁶, ¹Rush University Medical Center, Chicago, IL, ²Johns Hopkins University, Baltimore, ³Johns Hopkins University School of Medicine, Ellicott City, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Johns Hopkins Univerisity, Ellicott City, MD, ⁶Johns Hopkins University, Baltimore, MD
Background/Purpose: Ectopic soft tissue deposition of hydroxyapatite (calcinosis) is a frequent and morbid complication of dermatomyositis and scleroderma with no known effective pharmacologic treatment. 18F-NaF…
Abstract Number: 1058 • ACR Convergence 2020
The Relationship of Different Muscle Enzymes in Adult Myositis Patients
Rohit Aggarwal¹ and Tanya Chandra², ¹University of Pittsburgh, Pittsburgh, PA, ²University of Connecticut, HARTFORD, CT
Background/Purpose: Muscle enzymes are a core set measure (CSM) in clinical trials. The 2016 ACR/EULAR myositis response criteria and the IMACS definition of improvement recommend…
Abstract Number: 1556 • ACR Convergence 2020
Assessing Calcinosis in Dermatomyositis with Computed Tomography and Calcium Scoring
Prateek Gowda¹, Briana Cervantes², Lisa G. Rider³, Frederick W. Miller⁴, Marcus Chen⁴ and Adam Schiffenbauer⁴, ¹NIBIB, Baltimore, MD, ²NIEHS, Silver Spring, MD, ³Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, ⁴National Institutes of Health, Bethesda, MD
Background/Purpose: Calcinosis is a condition in which calcium salts are deposited in and around soft tissue and is observed in up to 30% of adult…
Abstract Number: 1061 • ACR Convergence 2020
Daily Myositis Symptom Changes Collected via a Smartphone-Based App Are Associated with Flare Occurrence – Providing Evidence of Potential Digital Biomarkers
Alexander Oldroyd¹, Belay Yimer², Max Little³, William Dixon² and Hector Chinoy⁴, ¹University of Manchester, Manchester, United Kingdom, ²Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom, ³University of Birmingham, Birmingham, United Kingdom, ⁴The University of Manchester, Manchester, United Kingdom
Background/Purpose: The concept of idiopathic inflammatory myopathy (IIM) flare is widely used, although no consensus definition exists. Studies have demonstrated the feasibility and utility of…
Abstract Number: 1639 • ACR Convergence 2020
Preliminary Baseline Subject Demographics and Disease Characteristics in a Phase 3 Clinical Trial of the Safety and Efficacy of Lenabasum in Dermatomyositis (DETERMINE)
Victoria Werth¹, Chester Oddis², David Fiorentino³, Nancy Dgetluck⁴, Quinn Dinh⁵, Michael Tillinger⁶, Barbara White⁵ and Ingrid Lundberg⁷, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ³Department of Dermatology, Stanford University, Redwood City, CA, ⁴Corbus Pharmaceuticals, Inc., Norwood, MA, ⁵Corbus Pharmaceuticals, Norwood, MA, ⁶Corbus Pharmaceuticals Inc., Norwood, MA, ⁷Division of Rheumatology, Department of Medicine, Karolinska Institutet,, Stockholm, Sweden
Background/Purpose: There is significant unmet need for new treatments to achieve disease control in dermatomyositis (DM), because of limited efficacy or toxicity of immunosuppressive agents…
Abstract Number: 1062 • ACR Convergence 2020
Dermatomyositis: A Dermatology-Rheumatology Clinic Retrospective Analysis
Burak Elkiran¹, Mahroo Tajalli², Terrence M. Vance³, Abrar A. Qureshi⁴ and Anthony M. Reginato⁵, ¹Department of Medicine, Division of Rheumatology; Warren Alpert Medical School of Brown University, BOSTON, ²Department of Dermatology, Warren Alpert Medical School of Brown University, PROVIDENCE, ³Department of Epidemiology, Warren Alpert Medical School of Brown University, PROVIDENCE, ⁴Department of Dermatology, Warren Alpert Medical School of Brown University, BOSTON, ⁵Department of Medicine, Division of Rheumatology, Warren Alpert Medical School of Brown University, Boston, MA
Background/Purpose: Dermatomyositis (DM) can be categorized into two major subtypes: clinically amyopathic dermatomyositis (CADM) and classic dermatomyositis (CDM). In this study, we aimed to identify characteristics…
Abstract Number: 1695 • ACR Convergence 2020
Anti-Melanoma Differentiation Associated Protein 5 (MDA5) Positive Juvenile Dermatomyositis: Focus on the Lung
David Moreno McNeill¹, Miriah Gillispie-Taylor², Kevin Baszis³, Edouard Sayad¹, Manuel Silva Carmona¹ and Tiphanie Vogel¹, ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, ³Washington Univ School of Medicine, St Louis, MO
Background/Purpose: A subset of juvenile dermatomyositis (JDM), clinically amyopathic dermatomyositis (CADM), is uncommon and mainly described in adults. CADM is classically characterized by skin ulcerations,…
Abstract Number: 1063 • ACR Convergence 2020
Spirulina Stimulates Inflammatory Cytokine Production Through the STING and TLR Pathways in Dermatomyositis in Vitro
Christina Bax¹, Yubin Li¹, Spandana Maddukuri², Adarsh Ravishankar³, Jay Patel³, Daisy Yan¹, Josef Symon Concha¹ and Victoria Werth¹, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia
Background/Purpose: Spirulina, a popular herbal supplement, stimulates the immune system, as determined by in vitro and in vivo studies. Our recent epidemiologic data suggest that Spirulina…
Abstract Number: 1916 • ACR Convergence 2020
KZR-616, a First-in-class Selective Inhibitor of the Immunoproteasome, Ameliorates Polymyositis in a Murine Model
Marta Del Rio Oliva¹, Michael Basler¹, Darrin Bomba², Diana Lam², Jennifer Brandl², Christopher Kirk² and Marcus Groettrup¹, ¹University of Konstanz, Konstanz, Germany, ²Kezar Life Sciences, Inc, San Francisco, CA
Background/Purpose: Polymyositis (PM) is a chronic autoimmune inflammatory myopathy affecting striated muscles and resulting in muscle weakness. PM is a rare disease, and there are…
Abstract Number: 1065 • ACR Convergence 2020
Immunostimulatory Herbal Supplement Use Is More Common Among Patients with Dermatomyositis
Adarsh Ravishankar¹, Daisy Yan², Christina Bax³, Josef Symon Concha², Bridget Shields⁴, Lisa Pappas-Taffer⁴, Rui Feng⁵, Joyce Okawa⁴ and Victoria Werth², ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³University of Pennsylvania, Department of Dermatology, Philadelphia, ⁴Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia
Background/Purpose: The use of complementary and alternative medicine (CAM) is prevalent in dermatology. Certain CAMs, including Spirulina, Alfalfa, Chlorella, Echinacea, and Blue-Green Algae have been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].